Imaging cellular distribution of Bcl inhibitors using small molecule drug conjugates

Bioconjug Chem. 2014 Nov 19;25(11):2081-5. doi: 10.1021/bc500433k. Epub 2014 Nov 3.

Abstract

Overexpression of anti-apoptotic proteins such as Bcl-2 is a cellular mechanism to evade apoptosis; consequently, Bcl-2 inhibitors are being developed as anticancer agents. In this work, we have synthesized a fluorescent version of ABT-199 in an effort to visualize a drug surrogate by high resolution imaging. We show that this fluorescent conjugate has comparable Bcl-2 binding efficacy and cell line potency to the parent compound and can be used as an imaging agent in several cancer cell types. We anticipate that this agent will be a valuable tool for studying the single-cell distribution and pharmacokinetics of ABT-199 as well the broader group of BH3-mimetics.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Apoptosis
  • Biological Transport
  • Boron Compounds / chemistry
  • Bridged Bicyclo Compounds, Heterocyclic / chemistry
  • Bridged Bicyclo Compounds, Heterocyclic / metabolism*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Cell Line, Tumor
  • Fluorescent Dyes / chemistry
  • Fluorescent Dyes / metabolism*
  • Fluorescent Dyes / pharmacology
  • Humans
  • Intracellular Space / metabolism
  • Models, Molecular
  • Molecular Imaging / methods*
  • Protein Conformation
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-bcl-2 / chemistry
  • Sulfonamides / chemistry
  • Sulfonamides / metabolism*
  • Sulfonamides / pharmacology

Substances

  • 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene
  • Boron Compounds
  • Bridged Bicyclo Compounds, Heterocyclic
  • Fluorescent Dyes
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • venetoclax